ACAD ACADIA Pharmaceuticals Inc. - Common Stock
NASDAQ · Biotechnology · Lihat di SEC EDGAR ↗ tutup Okt 2, 2026 10-K/10-Q Agu 5, 2026
$19,95
· % dari rentang 52 mgg
· di atas terendah
· ke tinggi
$19,59rendah 52m
$30,96tinggi 52m
Kapitalisasi Pasar (MRQ)
$3.43B
P/E (TTM)
8.9
EPS (TTM)
$2.23
Pendapatan (TTM)
$1.14B
lencana Anda
Rentang 52M
$20–$31
Peringkat Analis
BUY
Target Harga
$32
P/E
8.9
ROE
35.7%
Margin Laba Bersih
33.4%
Strip lencana Anda kosong — sematkan metrik di mana saja di halaman ini.
ACAD Cuplikan Saham Harga, kapitalisasi pasar, P/E, EPS, ROE, utang/ekuitas, kisaran 52 minggu
Harga
$19.95
Kapitalisasi Pasar (MRQ)
$3.43B
P/E (TTM)
8.9
EPS (TTM)
$2.23
Pendapatan (TTM)
$1.14B
ROE (TTM)
35.7%
Rentang 52M
$20–$31
ACAD Grafik Harga Saham OHLCV harian dengan indikator teknis — geser, perbesar, dan sesuaikan tampilan Anda
rentang
batang
Granularitas batang menyesuaikan dengan periode yang dipilih — arahkan kursor ke bagan untuk melihat buka/tinggi/rendah/tutup untuk sebuah batang.
Tentang ACADIA Pharmaceuticals Inc. - Common Stock Tinjauan perusahaan dari Wikipedia
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, California.
Product development
Nuplazid, a drug developed by Acadia in the late 1990s, "was designed to stimulate a subset of the brain’s serotonin receptors, or the proteins that govern memory, cognition and learning." On April 29, 2016, the FDA approved Acadia's drug, Nuplazid, for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. Nuplazid is the trade name for Acadia's proprietary molecule, pimavanserin, a selective serotonin inverse agonist preferentially targeting 5-HT2a receptors. Acadia had partnered with Biovail in the late-stage clinical testing of the drug, which showed trial failures as of 2009.
Acadia is running multiple Phase 2 and Phase 3 trials with pimavanserin in several central nervous system conditions: dementia-related psychosis, major depressive disorder, schizophrenia inadequate response, and schizophrenia negative symptoms.
As of 1997, Acadia was among several companies that licensed compounds from Genzyme's small-molecule compound library.
In 2023, the FDA approved trofinetide (marketed as Daybue) for use in Rett syndrome.
History
Acadia started in 1993 as Receptor Technologies, based in Winooski, Vermont. In 1997, the company relocated all operations and management from Vermont to San Diego, California, as a strategic move to garner partnerships with other biotechnology companies. However, the company also had an office in Denmark, in which it received a crucial part of its early investments from BankInvest, under managing director Florian Schönharting, Kommunernes Pensionsforsikring A/S and Dansk Kapitalanlæg Aktieselskab as well as private investor Lars Christiansen. At the time, the company had fifty employees, fourteen of whom were in the Denmark office. The focus of the company in its early years was on genetic screens for receptors, aiming to accelerate early stage drug discovery.
The company planned to conduct an initial public offering (IPO) consisting of 31.6% of the company in 2001, with the intention of raising US$64 million and listing on the NASDAQ exchange under the symbol ACAD. At the time, Acadia and Allergan were collaborating on development of a treatment for glaucoma, and Allergan would retain a 6.3% ownership stake in Acadia after the IPO. However, the company's IPO, which ultimately took place in May 2004, did not fare as well as expected and netted only US$35 million. At the time, the company had five drugs in development and was running two in human trials. The company had a subsequent round of stock offering in May 2007 which raised US$102 million.
In September 2020, Acadia Pharmaceuticals acquired clinical-stage biotechnology company CerSci Therapeutics.
Corporate governance
In 2001, the company's chief executive officer at the time, Leonard R. Borrmann, left Acadia to lead Maret Pharmaceuticals. He was succeeded by Uli Hacksell, who left Acadia to lead Cerecor at the beginning of 2016.
== References ==
Sumber: Wikipedia (English), CC BY-SA 4.0 · Lihat di Wikipedia ↗
sektorHealthcare
industriBiotechnology
karyawan796
negaraUS
Kinerja 10 Tahun Tren Pendapatan, laba bersih, margin, dan EPS
Pendapatan$1.07B2016-12-31 → 2025-12-31
EPS$2.302020-12-31 → 2025-12-31
Arus Kas Bebas$105M2016-12-31 → 2025-12-31
Margin bersih33.4%2016-12-31 → 2025-12-31
Valuasi & Rasio
Valuasi Rasio P/E, P/S, P/B, EV/EBITDA — apakah sahamnya mahal atau murah?
| Metrik | Tren 5 Tahun | ACAD | rata-rata 5T | Median Rekan | Kesimpulan |
|---|---|---|---|---|---|
| P/E (TTM) | 8.9rata-rata 5T ≈-18.7 | ≈-18.7 | 13.8 | Kurang nilai | |
| P/S (TTM) | 3.0rata-rata 5T ≈5.5 | ≈5.5 | 11.9 | Kurang nilai | |
| P/B (MRQ) | 2.6rata-rata 5T ≈6.6 | ≈6.6 | 3.4 | Kurang nilai | |
| Harga / FCF (TTM) | 23.6rata-rata 5T ≈64.0 | ≈64.0 | · | · | |
| Harga / Arus Kas (TTM) | 21.4rata-rata 5T ≈63.4 | ≈63.4 | · | · | |
| Harga / Nilai Buku Berwujud (MRQ) | 2.9rata-rata 5T ≈7.3 | ≈7.3 | · | · |
Median rekan dihitung berdasarkan basis standar per metrik dan mungkin tidak selalu cocok dengan basis TTM/MRQ yang ditampilkan untuk saham ini.
Profitabilitas Margin kotor, operasional, dan bersih; ROE, ROA, ROIC
| Metrik | Tren 5 Tahun | ACAD | rata-rata 5T | Median Rekan | Kesimpulan |
|---|---|---|---|---|---|
| Margin Operasi (TTM) | 7.6%rata-rata 5T ≈-10.9% | ≈-10.9% | 12.5% | Sejajar | |
| EBITDA Margin (Margin EBITDA) | 9.8%rata-rata 5T ≈-10.9% | ≈-10.9% | 12.5% | Sejajar | |
| Margin Sebelum Pajak (TTM) | 10.7%rata-rata 5T ≈-8.6% | ≈-8.6% | 16.4% | Sejajar | |
| Margin Laba Bersih (TTM) | 33.4%rata-rata 5T ≈-4.9% | ≈-4.9% | 10.2% | Sejajar | |
| ROA (TTM) | 25.6%rata-rata 5T ≈-2.7% | ≈-2.7% | -7.4% | Tingkat teratas | |
| ROE (TTM) | 35.7%rata-rata 5T ≈-5.1% | ≈-5.1% | -10.7% | Tingkat teratas | |
| ROIC | 24.0%rata-rata 5T ≈-11.4% | ≈-11.4% | -3.0% | Tingkat teratas |
Kesehatan Keuangan Utang, likuiditas, solvabilitas — kekuatan neraca
| Metrik | Tren 5 Tahun | ACAD | rata-rata 5T | Median Rekan | Kesimpulan |
|---|---|---|---|---|---|
| Rasio Lancar (MRQ) | 3.4rata-rata 5T ≈3.8 | ≈3.8 | 6.5 | Likuiditas rendah | |
| Quick Ratio (Rasio Cepat) | 1.1rata-rata 5T ≈1.4 | ≈1.4 | 5.0 | Likuiditas rendah |
Pertumbuhan Pertumbuhan Pendapatan, EPS, dan Laba Bersih: YoY, CAGR 3T, CAGR 5T
| Metrik | Tren 5 Tahun | ACAD | rata-rata 5T | Median Rekan | Kesimpulan |
|---|---|---|---|---|---|
| Revenue YoY (Pendapatan YoY) | 11.9%rata-rata 5T ≈20.1% | ≈20.1% | · | · | |
| Revenue CAGR 3Y (CAGR Pendapatan 3T) | 27.5%rata-rata 5T ≈23.7% | ≈23.7% | · | · | |
| Revenue CAGR 5Y (CAGR Pendapatan 5T) | 19.4% | · | · | · | |
| EPS YoY | 69.1% | · | · | · | |
| Net Income YoY (Laba Bersih YoY) | 72.7% | · | · | · |
Efisiensi Modal Perputaran aset, perputaran persediaan, perputaran piutang
| Metrik | Tren 5 Tahun | ACAD | rata-rata 5T | Median Rekan | Kesimpulan |
|---|---|---|---|---|---|
| Asset Turnover (Perputaran Aset) | 0.8rata-rata 5T ≈0.9 | ≈0.9 | 0.4 | Tingkat teratas | |
| Inventory Turnover (Perputaran Persediaan) | 0.9rata-rata 5T ≈1.1 | ≈1.1 | · | · | |
| Receivables Turnover (Perputaran Piutang) | 9.7rata-rata 5T ≈9.1 | ≈9.1 | 10.5 | Sejajar | |
| Revenue / Employee (Pendapatan Tahunan ÷ karyawan (jumlah karyawan, yfinance). Turunan — bukan konsep SEC-XBRL yang tersimpan.) | ≈$1.3M | · | · | · |
nilai · ≈ rata-rata 5T · median industri · penilaian relatif terhadap median
Riwayat Pendapatan EPS aktual vs perkiraan, kejutan %, tingkat keberhasilan, tanggal pendapatan berikutnya
Kejutan Rata-rata
228.8%
Laporan Berikutnya
Nov 03, 2026
| Periode | Laporan | EPS Aktual | EPS Estimasi | Kejutan |
|---|---|---|---|---|
| 30 Juni 2026 | Agu 11, 2026 | $0.18 | $0.06 | 207.2% |
| 31 Maret 2026 | Mei 13, 2026 | $0.02 | $0.06 | -68.4% |
| 31 Des. 2025 | $1.60 | $0.14 | 1044.5% | |
| 30 Sep. 2025 | $0.42 | $0.15 | 178.1% | |
| 30 Juni 2025 | $0.16 | $0.14 | 14.4% | |
| 31 Maret 2025 | $0.11 | $0.11 | -3.2% |
Fundamental Lengkap Semua metrik per tahun — laporan laba rugi, neraca, arus kas
Laporan Laba Rugi
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.07B | $958M | $726M | $517M | $484M | $442M | $339M | $224M | $125M | $17M | $61.0K | $120.0K | |
| Cost of Revenue | $89M | $82M | $42M | $10M | $19M | $10M | $11M | $12M | $9M | $3M | · | · | |
| Gross Profit | · | · | $685M | $507M | $473M | $432M | $328M | $211M | $116M | $14M | · | · | |
| R&D Expense | $329M | $303M | $352M | $362M | $239M | $319M | $240M | $187M | $149M | $99M | $74M | $61M | |
| SG&A Expense | $549M | $488M | $407M | $369M | $396M | $389M | $326M | $266M | $255M | $186M | $88M | $33M | |
| Operating Expenses | $967M | $727M | $800M | $741M | $655M | $728M | $586M | $471M | $417M | $290M | $165M | $93M | |
| Operating Income | $105M | $231M | $-73M | $-224M | $-170M | $-287M | $-247M | $-247M | $-292M | $-273M | $-165M | $-93M | |
| Other Non-op | $2M | $2M | $5M | $4M | $2M | $-997.0K | $997.0K | $-2M | · | · | · | · | |
| Pretax Income | $139M | $258M | $-51M | $-213M | $-168M | $-281M | $-234M | $-244M | $-288M | $-270M | $-164M | $-92M | |
| Income Tax | $-252M | $32M | $10M | $3M | $351.0K | $611.0K | $876.0K | $1M | $1M | $1M | $330.0K | $0 | |
| Net Income | $391M | $226M | $-61M | $-216M | $-168M | $-282M | $-235M | $-245M | $-289M | $-271M | $-164M | $-92M | |
| EPS (Basic) | $2.32 | $1.37 | $-0.37 | $-1.34 | $-1.05 | $-1.79 | · | · | · | · | · | · | |
| EPS (Diluted) | $2.30 | $1.36 | $-0.37 | $-1.34 | $-1.05 | $-1.79 | · | · | · | · | · | · | |
| Shares (Basic) | 168,356,000 | 165,717,000 | 163,819,000 | 161,683,000 | 160,493 | 157,331 | · | · | · | · | · | · | |
| Shares (Diluted) | 169,919,000 | 166,362,000 | 163,819,000 | 161,683,000 | 160,493 | 157,331 | · | · | · | · | · | · | |
| EBITDA | $105M | $231M | $-73M | $-224M | $-170M | $-287M | $-247M | $-247M | $-292M | $-273M | $-165M | $-93M |
Neraca
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $178M | $320M | $189M | $115M | $147M | $326M | $190M | $135M | $69M | $164M | $102M | $62M | |
| Receivables | $121M | $99M | $98M | $62M | $64M | $48M | $36M | $26M | $17M | $6M | · | · | |
| Inventory | $111M | $92M | $40M | $12M | $14M | $10M | $6M | $4M | $5M | $4M | · | · | |
| Prepaid Expense | $60M | $56M | $39M | $21M | $24M | $26M | $19M | $21M | $8M | $8M | $2M | $1M | |
| Current Assets | $1.06B | $938M | $616M | $508M | $618M | $718M | $760M | $526M | $373M | $548M | $219M | $325M | |
| PP&E (Net) | $8M | $4M | $5M | $6M | $8M | $9M | $3M | $3M | $3M | $3M | $2M | $553.0K | |
| PP&E (Gross) | $17M | $14M | $14M | $14M | $14M | $13M | $9M | $8M | $7M | $6M | $5M | $3M | |
| Accum. Depreciation | $9M | $10M | $10M | $8M | $6M | $4M | $5M | $4M | $4M | $3M | $3M | $2M | |
| Intangibles | $109M | $120M | $65M | $0 | $0 | $1M | $3M | $4M | $6M | $7M | · | · | |
| Other Non-current Assets | $4M | $359.0K | $476.0K | $8M | $4M | $2M | $3M | $2M | $354.0K | $785.0K | $329.0K | $287.0K | |
| Total Assets | $1.56B | $1.19B | $749M | $588M | $700M | $783M | $783M | $540M | $385M | $561M | $222M | $325M | |
| Accounts Payable | $11M | $16M | $18M | $13M | $7M | $8M | $7M | $3M | $9M | $4M | $2M | $2M | |
| Accrued Liabilities | $266M | $379M | $237M | $113M | $89M | $97M | $68M | $56M | $40M | $36M | $20M | $14M | |
| Current Liabilities | $277M | $395M | $254M | $126M | $96M | $106M | $75M | $60M | $49M | $43M | $22M | $16M | |
| Capital Leases | $41M | $42M | $48M | $53M | $56M | $44M | $6M | · | · | · | · | · | |
| Deferred Tax | $11M | $11M | $12M | $13M | $14M | $13M | $3M | · | · | · | · | · | |
| Other Non-current Liabilities | $19M | $18M | $15M | $9M | $7M | $5M | $3M | $2M | · | · | · | · | |
| Total Liabilities | $337M | $455M | $317M | $187M | $159M | $156M | $84M | $61M | $49M | $43M | $22M | $16M | |
| Common Stock | $16.0K | $16.0K | $16.0K | $16.0K | $16.0K | $16.0K | $15.0K | $14.0K | $12.0K | $12.0K | $10.0K | $10.0K | |
| Paid-in Capital | · | · | · | · | · | · | · | · | · | $1.45B | $862M | $808M | |
| Retained Earnings | $-1.81B | $-2.20B | $-2.43B | $-2.37B | $-2.15B | $-1.99B | $-1.70B | $-1.47B | $-1.22B | $-934M | $-663M | $-498M | |
| AOCI | $1M | $292.0K | $24.0K | $-975.0K | $-192.0K | $36.0K | $297.0K | $-372.0K | $-399.0K | $106.0K | $11.0K | $-9.0K | |
| Stockholders' Equity | $1.23B | $733M | $432M | $400M | $541M | $627M | $699M | $479M | $335M | $518M | $200M | $309M | |
| Liabilities + Equity | $1.56B | $1.19B | $749M | $588M | $700M | $783M | $783M | $540M | $385M | $561M | $222M | $325M | |
| Shares Outstanding | 170,309,376 | 166,708,856 | 164,650,219 | 162,064,872 | 161,012,695 | 159,637,771 | 155,275,300 | 143,853,597 | 124,410,552 | 121,367,169 | 101,938,702 | 100,047,331 |
Arus Kas
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | · | · | · | · | · | · | · | · | · | $206.0K | |
| Stock-based Comp | $52M | $67M | $66M | $68M | $64M | $84M | $82M | $82M | $76M | $55M | $40M | $16M | |
| Deferred Tax | $-250M | $0 | $0 | $3M | $351.0K | · | · | · | · | · | · | · | |
| Amort. of Intangibles | $11M | $15M | $4M | $0 | $1M | $1M | $1M | $1M | $1M | $985.0K | $0 | $0 | |
| Operating Cash Flow | $110M | $158M | $17M | $-114M | $-126M | $-136M | $-151M | $-167M | $-218M | $-208M | $-122M | $-66M | |
| CapEx | $5M | $523.0K | $50.0K | $0 | $1M | $8M | $1M | $2M | $812.0K | $2M | $2M | $180.0K | |
| Investing Cash Flow | $-303M | $-31M | $32M | $73M | $-71M | $193M | $-166M | $-71M | $92M | $-262M | · | · | |
| Stock Issued | $50M | $7M | $25M | $8M | $18M | $81M | $372M | $307M | $31M | $519M | $15M | $204M | |
| Net Stock Activity | $50M | $7M | $25M | $8M | $18M | $81M | $372M | $307M | $31M | $519M | $15M | $204M | |
| Financing Cash Flow | $50M | $7M | $25M | $8M | $18M | $81M | $372M | $307M | $31M | $534M | · | · | |
| Net Change in Cash | $-143M | $134M | $74M | $-33M | $-179M | $137M | $55M | $68M | $-94M | $63M | $40M | $50M | |
| Taxes Paid | $25M | $20M | $6M | $2M | $1M | $1M | $2M | $1M | $1M | $-365.0K | $415.0K | · | |
| Free Cash Flow | $105M | $157M | $17M | $-114M | $-127M | $-144M | $-152M | $-170M | $-219M | $-212M | $-124M | $-67M |
Profitabilitas
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | · | · | 94.3% | 98.0% | 97.8% | 97.7% | 96.7% | 94.5% | 92.7% | 82.2% | · | · | |
| Operating Margin | 9.8% | 24.1% | -10.1% | -43.2% | -35.2% | -64.9% | -72.7% | -110.6% | -234.1% | -1574.1% | -269855.7% | -77691.7% | |
| Net Margin | 36.5% | 23.6% | -8.4% | -41.8% | -34.7% | -63.7% | -69.4% | -109.6% | -231.7% | -1565.9% | -269578.7% | -77062.5% | |
| Pretax Margin | 13.0% | 26.9% | -7.0% | -41.3% | -34.6% | -63.6% | -69.1% | -109.0% | -230.8% | -1558.2% | -269037.7% | · | |
| EBITDA Margin | 9.8% | 24.1% | -10.1% | -43.2% | -35.2% | -64.9% | -72.7% | -110.6% | -234.1% | -1574.1% | -269855.7% | -77691.7% | |
| ROA | 28.4% | 23.4% | -9.2% | -33.5% | -22.6% | -36.0% | -35.5% | -53.0% | -61.2% | -69.3% | -60.1% | -35.9% | |
| ROE | 38.1% | 34.6% | -15.4% | -52.3% | -30.3% | -43.9% | -33.9% | -69.8% | -67.8% | -75.6% | -64.6% | -37.6% | |
| ROIC | 24.0% | 27.6% | -20.4% | -56.5% | -31.6% | -45.8% | -35.4% | -51.9% | -87.5% | -52.9% | -82.6% | · |
Likuiditas & Solvabilitas
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.8 | 2.4 | 2.4 | 4.0 | 6.4 | 6.8 | 10.2 | 8.8 | 7.6 | 12.9 | 10.0 | 20.5 | |
| Quick Ratio | 1.1 | 1.1 | 1.1 | 1.4 | 2.2 | 3.5 | 3.0 | 2.7 | 1.8 | 4.0 | 4.7 | 3.9 |
Efisiensi
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.8 | 1.0 | 1.1 | 0.8 | 0.7 | 0.6 | 0.5 | 0.5 | 0.3 | 0.0 | 0.0 | 0.0 | |
| Inventory Turnover | 0.9 | 1.2 | 1.6 | 0.8 | 0.9 | 1.3 | 2.2 | · | 1.9 | 1.5 | · | · | |
| Receivables Turnover | 9.7 | 9.7 | 9.1 | 8.2 | 8.6 | 10.5 | 11.0 | 10.3 | 10.7 | 5.9 | · | · |
Per Saham
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $7.21 | $4.40 | $2.62 | $2.47 | $3.36 | $3.93 | $4.50 | $3.33 | $2.69 | $4.27 | $1.96 | $3.09 | |
| Revenue / Share | $6.31 | $5.76 | $4434.39 | $3199.07 | · | · | · | · | · | · | · | · | |
| Cash Flow / Share | $0.65 | $0.95 | $101.95 | $-705.30 | · | · | · | · | · | · | · | · | |
| Cash / Share | $1.04 | $1.92 | $1.15 | $0.71 | $0.92 | $2.04 | $1.22 | $0.94 | $0.56 | $1.35 | $1.00 | $0.62 | |
| EPS (TTM) | $2.30 | $1.36 | $-0.37 | $-1.34 | $-1.05 | $-1.79 | · | · | · | · | · | · |
Tingkat Pertumbuhan
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 11.9% | 31.9% | 40.5% | 6.8% | 9.6% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 27.5% | 25.5% | 18.0% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 19.4% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | 69.1% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | 72.7% | · | · | · | · | · | · | · | · | · | · | · |
Valuasi (TTM)
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $1.07B | $958M | $726M | $517M | $484M | $442M | $339M | $224M | $125M | $17M | $61.0K | $120.0K | |
| Net Income TTM | $391M | $226M | $-61M | $-216M | $-168M | $-282M | $-235M | $-245M | $-289M | $-271M | $-164M | $-92M | |
| Market Cap | $4.55B | $3.06B | $5.16B | $2.58B | $3.76B | $8.53B | $6.64B | $2.33B | $3.75B | $3.50B | $3.63B | $3.18B | |
| P/E | 11.6 | 13.5 | -84.6 | -11.9 | -22.2 | -29.9 | · | · | · | · | · | · | |
| P/S | 4.2 | 3.2 | 7.1 | 5.0 | 7.8 | 19.3 | 19.6 | 10.4 | 30.0 | 202.0 | 59575.7 | 26470.9 | |
| P/B | 3.7 | 4.2 | 11.9 | 6.4 | 6.9 | 13.6 | 9.5 | 4.9 | 11.2 | 6.8 | 18.2 | 10.3 | |
| P / Tangible Book | 4.1 | 5.0 | 14.1 | 6.4 | 6.9 | 13.6 | · | · | · | · | · | · | |
| P / Cash Flow | 41.4 | 19.4 | 308.7 | -22.6 | -29.9 | -62.7 | -44.0 | -13.9 | -17.2 | -16.6 | -29.8 | -47.8 | |
| P / FCF | 43.3 | 19.5 | 309.6 | -22.6 | -29.6 | -59.4 | -43.6 | -13.7 | -17.1 | -16.5 | -29.3 | -47.7 | |
| Earnings Yield | 8.6% | 7.4% | -1.2% | -8.4% | -4.5% | -3.4% | · | · | · | · | · | · |
Laporan Laba Rugi
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $308M | $268M | $284M | $279M | $265M | $244M | $260M | $250M | $242M | $206M | $231M | $212M | $165M | $118M | $136M | $131M | |
| Cost of Revenue | $28M | $25M | $26M | $22M | $21M | $20M | $22M | $19M | $18M | $23M | $18M | $15M | $7M | $2M | $2M | $2M | |
| Gross Profit | · | · | · | · | · | · | · | · | · | · | $213M | $197M | $158M | $117M | $134M | $129M | |
| R&D Expense | $82M | $77M | $85M | $88M | $78M | $78M | $101M | $67M | $76M | $60M | $67M | $157M | $59M | $69M | $76M | $81M | |
| SG&A Expense | $160M | $171M | $156M | $133M | $134M | $126M | $130M | $133M | $117M | $108M | $111M | $98M | $96M | $101M | $104M | $78M | |
| Operating Expenses | $270M | $273M | $267M | $243M | $232M | $225M | $106M | $219M | $212M | $191M | $196M | $269M | $162M | $172M | $183M | $162M | |
| Operating Income | $38M | $-5M | $17M | $36M | $32M | $19M | $154M | $32M | $30M | $15M | $35M | $-58M | $3M | $-54M | $-46M | $-31M | |
| Other Non-op | $647.0K | $542.0K | $596.0K | $593.0K | $594.0K | $588.0K | $575.0K | $576.0K | $386.0K | $286.0K | $0 | $2M | $-1M | $5M | $2M | $2M | |
| Pretax Income | $46M | $4M | $26M | $45M | $40M | $28M | $161M | $39M | $37M | $21M | $40M | $-52M | $6M | $-45M | $-41M | $-26M | |
| Income Tax | $15M | $344.0K | $-247M | $-27M | $14M | $9M | $17M | $6M | $4M | $4M | $-6M | $13M | $5M | $-2M | $835.0K | $768.0K | |
| Net Income | $32M | $4M | $274M | $72M | $27M | $19M | $144M | $33M | $33M | $17M | $46M | $-65M | $1M | $-43M | $-42M | $-27M | |
| EPS (Basic) | $0.18 | $0.02 | $1.62 | $0.43 | $0.16 | $0.11 | $0.87 | $0.20 | $0.20 | $0.10 | $0.29 | $-0.40 | $0.01 | $-0.27 | $-0.26 | $-0.17 | |
| EPS (Diluted) | $0.18 | $0.02 | $1.61 | $0.42 | $0.16 | $0.11 | $0.86 | $0.20 | $0.20 | $0.10 | $0.29 | $-0.40 | $0.01 | $-0.27 | $-0.26 | $-0.17 | |
| Shares (Basic) | 171,603,000 | 170,517,000 | · | 168,836,000 | 167,827,000 | 166,808,000 | · | 165,974,000 | 165,551,000 | 164,798,000 | · | 164,234,000 | 163,458,000 | 162,263,000 | · | 161,852 | |
| Shares (Diluted) | 172,851,000 | 172,706,000 | · | 170,650,000 | 168,681,000 | 167,668,000 | · | 166,178,000 | 166,174,000 | 166,623,000 | · | 164,234,000 | 165,046,000 | 162,263,000 | · | 161,852 | |
| EBITDA | $38M | $-5M | · | $36M | $32M | $19M | · | $32M | $30M | $15M | · | $-58M | $3M | $-54M | · | $-31M |
Neraca
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $385M | $282M | $178M | $258M | $254M | $218M | $320M | $155M | $177M | $205M | $189M | $98M | $108M | $291M | $115M | $155M | |
| Receivables | $151M | $135M | $121M | $116M | $108M | $106M | $99M | $98M | $104M | $95M | · | $93M | $82M | $66M | · | $56M | |
| Inventory | $109M | $112M | $111M | $106M | $111M | $103M | $92M | $87M | $86M | $67M | · | $25M | $14M | $11M | · | $12M | |
| Prepaid Expense | $69M | $65M | $60M | $61M | $53M | $53M | $56M | $52M | $46M | $43M | · | $38M | $24M | $24M | · | $23M | |
| Current Assets | $1.22B | $1.10B | $1.06B | $1.08B | $961M | $871M | $938M | $788M | $729M | $675M | · | $499M | $493M | $503M | · | $522M | |
| PP&E (Net) | $17M | $15M | $8M | $4M | $4M | $3M | $4M | $4M | $4M | $4M | · | $5M | $5M | $6M | · | $7M | |
| PP&E (Gross) | · | · | $17M | · | · | · | $14M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $9M | · | · | · | $10M | · | · | · | · | · | · | · | · | · | |
| Intangibles | $103M | $106M | $109M | $112M | $114M | $117M | $120M | $106M | $108M | $110M | · | $67M | $68M | $70M | · | · | |
| Other Non-current Assets | $4M | $4M | $4M | $3M | $2M | $1M | $359.0K | $359.0K | $476.0K | $476.0K | · | $475.0K | $11M | $12M | · | $6M | |
| Total Assets | $1.74B | $1.61B | $1.56B | $1.33B | $1.23B | $1.13B | $1.19B | $977M | $914M | $855M | · | $633M | $643M | $655M | · | $602M | |
| Accounts Payable | $45M | $12M | $11M | $22M | $20M | $18M | $16M | $19M | $20M | $19M | · | $12M | $19M | $17M | · | $10M | |
| Accrued Liabilities | $317M | $293M | $266M | $335M | $310M | $284M | $379M | $325M | $318M | $311M | · | $197M | $169M | $207M | · | $107M | |
| Current Liabilities | $361M | $306M | $277M | $357M | $330M | $303M | $395M | $344M | $338M | $331M | · | $210M | $188M | $224M | · | $117M | |
| Capital Leases | $60M | $39M | $41M | $43M | $45M | $45M | $42M | $40M | $47M | $49M | · | $48M | $50M | $51M | · | $54M | |
| Deferred Tax | · | · | $11M | · | · | · | $11M | · | · | · | · | · | · | · | · | · | |
| Other Non-current Liabilities | $15M | $13M | $19M | $14M | $29M | $20M | $18M | $15M | $12M | $11M | · | $13M | $9M | $5M | · | $6M | |
| Total Liabilities | $436M | $357M | $337M | $413M | $403M | $367M | $455M | $400M | $397M | $391M | · | $270M | $247M | $281M | · | $177M | |
| Common Stock | $16.0K | $16.0K | $16.0K | $16.0K | $16.0K | $16.0K | $16.0K | $16.0K | $16.0K | $16.0K | · | $16.0K | $16.0K | $16.0K | · | $16.0K | |
| Retained Earnings | $-1.78B | $-1.81B | $-1.81B | $-2.09B | $-2.16B | $-2.19B | $-2.20B | $-2.35B | $-2.38B | $-2.41B | · | $-2.48B | $-2.41B | $-2.41B | · | $-2.33B | |
| AOCI | $-958.0K | $-563.0K | $1M | $989.0K | $406.0K | $437.0K | $292.0K | $858.0K | $-339.0K | $-229.0K | · | $-319.0K | $-535.0K | $-220.0K | · | $-1M | |
| Stockholders' Equity | $1.31B | $1.25B | $1.23B | $917M | $822M | $765M | $733M | $577M | $517M | $464M | $432M | $362M | $396M | $374M | $400M | $426M | |
| Liabilities + Equity | $1.74B | $1.61B | $1.56B | $1.33B | $1.23B | $1.13B | $1.19B | $977M | $914M | $855M | · | $633M | $643M | $655M | · | $602M | |
| Shares Outstanding | 172,132,442 | 171,086,205 | 170,309,376 | 169,146,043 | 168,607,881 | 167,116,045 | 166,708,856 | 166,351,715 | 165,853,301 | 164,959,736 | · | 163,968,949 | 163,355,787 | 162,384,178 | · | 161,871,806 |
Arus Kas
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $17M | $15M | $13M | $13M | $14M | $11M | $10M | $26M | $16M | $15M | $18M | $19M | $15M | $15M | $14M | $18M | |
| Amort. of Intangibles | $3M | $3M | $3M | $3M | $3M | $3M | $5M | $2M | $2M | $5M | $1M | $1M | $1M | $0 | $0 | $0 | |
| Operating Cash Flow | $101M | $34M | $-49M | $74M | $64M | $20M | $40M | $63M | $25M | $29M | $85M | $-59M | $8M | $-18M | $-24M | $-727.0K | |
| CapEx | $5M | $5M | $4M | $388.0K | $297.0K | $0 | $453.0K | $70.0K | · | · | $0 | · | · | · | $0 | $0 | |
| Investing Cash Flow | $-9M | $66M | $-56M | $-79M | $-43M | $-124M | $122M | $-82M | $-56M | $-14M | $-347.0K | $34M | $-194M | $193M | $-18M | $15M | |
| Stock Issued | $10M | $4M | $23M | $9M | $16M | $2M | $2M | $268.0K | $4M | $1M | $5M | $13M | $5M | $1M | $2M | $287.0K | |
| Net Stock Activity | · | $4M | · | · | · | $2M | · | · | · | $1M | · | · | · | $1M | · | · | |
| Financing Cash Flow | $10M | $4M | $23M | $9M | $16M | $2M | $2M | $268.0K | $4M | $1M | $5M | $13M | $5M | $1M | $2M | $287.0K | |
| Net Change in Cash | $103M | $105M | $-82M | $4M | $37M | $-102M | $164M | $-19M | $-28M | $16M | $90M | $-12M | $-181M | $176M | $-40M | $15M | |
| Free Cash Flow | · | $29M | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
Profitabilitas
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 12.3% | -1.7% | · | 12.8% | 12.2% | 7.9% | · | 12.6% | 12.6% | 7.4% | · | -27.3% | 1.8% | -45.2% | · | -23.6% | |
| Net Margin | 10.2% | 1.4% | · | 25.8% | 10.1% | 7.8% | · | 13.1% | 13.8% | 8.0% | · | -30.8% | 0.67% | -36.3% | · | -20.8% | |
| Pretax Margin | 15.1% | 1.5% | · | 16.0% | 15.2% | 11.4% | · | 15.5% | 15.4% | 10.2% | · | -24.6% | 3.8% | -37.9% | · | -20.2% | |
| EBITDA Margin | 12.3% | -1.7% | · | 12.8% | 12.2% | 7.9% | · | 12.6% | 12.6% | 7.4% | · | -27.3% | 1.8% | -45.2% | · | -23.6% | |
| ROA | 2.1% | 0.27% | · | 6.2% | 2.5% | 1.9% | · | 4.1% | 4.3% | 2.2% | · | -10.5% | 0.18% | -6.7% | · | -4.1% | |
| ROE | 3.0% | 0.36% | · | 9.6% | 4.0% | 3.1% | · | 7.0% | 7.3% | 4.0% | · | -16.6% | 0.27% | -10.5% | · | -5.5% | |
| ROIC | 2.0% | -0.34% | · | 6.3% | 2.6% | 1.7% | · | 4.6% | 5.3% | 2.6% | · | -19.9% | 0.13% | -13.7% | · | -7.5% |
Likuiditas & Solvabilitas
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.4 | 3.6 | · | 3.0 | 2.9 | 2.9 | · | 2.3 | 2.2 | 2.0 | · | 2.4 | 2.6 | 2.2 | · | 4.5 | |
| Quick Ratio | 1.5 | 1.4 | · | 1.0 | 1.1 | 1.1 | · | 0.7 | 0.8 | 0.9 | · | 0.9 | 1.0 | 1.6 | · | 1.8 |
Efisiensi
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.3 | 0.3 | 0.3 | · | 0.3 | 0.3 | 0.2 | · | 0.2 | |
| Inventory Turnover | 0.3 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.3 | 0.4 | 0.6 | · | 0.8 | 0.6 | 0.1 | · | 0.2 | |
| Receivables Turnover | 2.4 | 2.2 | · | 2.6 | 2.5 | 2.4 | · | 2.6 | 2.6 | 2.6 | · | 2.9 | 2.2 | 1.8 | · | 2.2 |
Per Saham
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $7.59 | $7.29 | · | $5.42 | $4.88 | $4.58 | · | $3.47 | $3.12 | $2.81 | · | $2.21 | $2.42 | $2.30 | · | $2.63 | |
| Revenue / Share | $1.78 | $1.55 | · | $1.63 | $1.57 | $1.46 | · | $1.51 | $1.46 | $1.24 | · | $1289.01 | $1001.15 | $0.73 | · | $807.61 | |
| Cash Flow / Share | · | $0.20 | · | · | · | $0.12 | · | · | · | $0.17 | · | · | · | $-0.11 | · | · | |
| Cash / Share | $2.24 | $1.65 | · | $1.53 | $1.50 | $1.30 | · | $0.93 | $1.07 | $1.24 | · | $0.60 | $0.66 | $1.79 | · | $0.96 | |
| EPS (TTM) | $2.23 | $2.21 | · | $1.55 | $1.33 | $1.37 | · | $0.79 | $0.19 | $0.00 | · | $-0.92 | $-0.69 | $-0.91 | · | $-1.35 |
Valuasi (TTM)
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $1.14B | $1.10B | · | $1.05B | $1.02B | $996M | · | $929M | $891M | $814M | · | $632M | $551M | $520M | · | $512M | |
| Net Income TTM | $380M | $376M | · | $261M | $222M | $229M | · | $129M | $31M | $-2M | · | $-149M | $-111M | $-146M | · | $-217M | |
| Market Cap | $4.35B | $3.81B | · | $3.61B | $3.64B | $2.78B | · | $2.56B | $2.70B | $3.05B | · | $3.42B | $3.91B | $3.06B | · | $2.65B | |
| P/E | 11.3 | 10.1 | · | 13.8 | 16.2 | 12.1 | · | 19.5 | 85.5 | · | · | -22.7 | -34.7 | -20.7 | · | -12.1 | |
| P/S | 3.8 | 3.5 | · | 3.4 | 3.6 | 2.8 | · | 2.8 | 3.0 | 3.7 | · | 5.4 | 7.1 | 5.9 | · | 5.2 | |
| P/B | 3.3 | 3.1 | · | 3.9 | 4.4 | 3.6 | · | 4.4 | 5.2 | 6.6 | · | 9.4 | 9.9 | 8.2 | · | 6.2 | |
| P / Tangible Book | 3.6 | 3.3 | · | 4.5 | 5.1 | 4.3 | · | 5.4 | 6.6 | 8.6 | · | 11.6 | 11.9 | 10.0 | · | 6.2 | |
| P / Cash Flow | · | 112.1 | · | · | · | 136.6 | · | · | · | 104.9 | · | · | · | -170.4 | · | · | |
| Earnings Yield | 8.8% | 9.9% | · | 7.3% | 6.2% | 8.2% | · | 5.1% | 1.2% | 0.00% | · | -4.4% | -2.9% | -4.8% | · | -8.2% |
Periode terbaru di sebelah kiri · nilai null ditampilkan sebagai ·
Laporan Keuangan Laporan laba rugi, neraca, arus kas — tahunan, 5 tahun terakhir
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Pendapatan | $1.07B | $958M | $726M | $517M | $484M |
| Margin Kotor % | · | · | 94.3% | 98.0% | 97.8% |
| Margin Operasi % | 9.8% | 24.1% | -10.1% | -43.2% | -35.2% |
| Laba Bersih | $391M | $226M | $-61M | $-216M | $-168M |
| EPS Dilusian | $2.30 | $1.36 | $-0.37 | $-1.34 | $-1.05 |
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Rasio Lancar | 3.8 | 2.4 | 2.4 | 4.0 | 6.4 |
| Rasio Cepat | 1.1 | 1.1 | 1.1 | 1.4 | 2.2 |
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Arus Kas Bebas | $105M | $157M | $17M | $-114M | $-127M |
Pemilik institusional (13F) 385 pengaju · $4.7B total · Per tanggal 30 Sep. 2026
Institusi yang melaporkan kepemilikan saham ini dalam SEC Form 13F triwulanan mereka. Hanya posisi panjang; satu pengaju dapat muncul dua kali untuk leg opsi terpisah. Kaki put/call offset yang besar biasanya mencerminkan pembuatan pasar atau inventaris yang dilindungi, bukan keyakinan arah.
Pemegang
385
Nilai yang dipegang
$4.7B
Posisi baru
49
Posisi yang keluar
36
Aktivitas institusional — Q2 2026 vs kuartal sebelumnya
| Posisi baru | Posisi yang keluar | Meningkat | Menurun | Perubahan bersih saham |
|---|---|---|---|---|
| 49 (-4 vs Kuartal sebelumnya) | 36 (+8 vs Kuartal sebelumnya) | 135 (+15 vs Kuartal sebelumnya) | 115 (-7 vs Kuartal sebelumnya) | +4.6M |
Dibandingkan dengan Q1 2026. Pengajuan Formulir 13F SEC jatuh tempo dalam waktu 45 hari setelah akhir kuartal ditambah kelonggaran singkat untuk pengaju terlambat — kuartal yang masih dalam jangka waktu tersebut dilewati demi pasangan terakhir yang dilaporkan sepenuhnya.
| Institusi | Nilai | Saham | % dari 13F yang dilacak | Tipe |
|---|---|---|---|---|
| BAKER BROS. ADVISORS LP | $1.085.696.471 | 42.912.904 | 23,31% | Saham |
| BlackRock, Inc. | $569.633.876 | 22.515.173 | 12,23% | Saham |
| VANGUARD GROUP INC | $404.762.192 | 15.153.957 | 8,69% | Saham |
| STATE STREET CORP | $229.628.164 | 9.076.212 | 4,93% | Saham |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $223.612.785 | 8.838.450 | 4,80% | Saham |
| RTW INVESTMENTS, LP | $180.756.457 | 7.144.524 | 3,88% | Saham |
| VANGUARD CAPITAL MANAGEMENT LLC | $145.822.875 | 5.763.750 | 3,13% | Saham |
| DIMENSIONAL FUND ADVISORS LP | $93.482.749 | 3.694.988 | 2,01% | Saham |
| GEODE CAPITAL MANAGEMENT, LLC | $84.977.229 | 3.358.129 | 1,82% | Saham |
| Palo Alto Investors LP | $72.461.629 | 2.864.096 | 1,56% | Saham |
| GOLDMAN SACHS GROUP INC | $65.276.910 | 2.580.115 | 1,40% | Saham |
| Qube Research & Technologies Ltd | $61.899.233 | 2.446.610 | 1,33% | Saham |
| Point72 Asset Management, L.P. | $61.559.150 | 2.433.168 | 1,32% | Saham |
| CITADEL ADVISORS LLC | $55.209.078 | 2.182.177 | 1,19% | Saham |
| Pictet Asset Management Holding SA | $50.146.450 | 1.983.198 | 1,08% | Saham |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $49.826.959 | 1.969.445 | 1,07% | Saham |
| MARSHALL WACE, LLP | $44.650.402 | 1.764.838 | 0,96% | Saham |
| D. E. Shaw & Co., Inc. | $42.957.806 | 1.697.937 | 0,92% | Saham |
| BRAIDWELL LP | $41.653.895 | 1.646.399 | 0,89% | Saham |
| NORGES BANK | $41.069.692 | 1.623.308 | 0,88% | Saham |
| Frazier Life Sciences Management, L.P. | $36.386.409 | 1.438.198 | 0,78% | Saham |
| NORTHERN TRUST CORP | $34.595.776 | 1.367.422 | 0,74% | Saham |
| Nuveen, LLC | $34.109.259 | 1.348.192 | 0,73% | Saham |
| Artisan Partners Limited Partnership | $33.525.890 | 1.325.134 | 0,72% | Saham |
| BANK OF AMERICA CORP /DE/ | $32.899.740 | 1.300.385 | 0,71% | Saham |
| RENAISSANCE TECHNOLOGIES LLC | $32.449.679 | 1.282.596 | 0,70% | Saham |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $30.520.301 | 1.206.336 | 0,66% | Saham |
| Allspring Global Investments Holdings, LLC | $28.540.663 | 1.132.566 | 0,61% | Saham |
| Rockefeller Capital Management L.P. | $25.690.127 | 1.015.420 | 0,55% | Saham |
| MORGAN STANLEY | $23.949.976 | 946.639 | 0,51% | Saham |
| TWO SIGMA INVESTMENTS, LP | $23.452.898 | 926.992 | 0,50% | Saham |
| VANGUARD FIDUCIARY TRUST CO | $23.082.961 | 912.370 | 0,50% | Saham |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | $21.642.506 | 855.435 | 0,46% | Saham |
| Invesco Ltd. | $20.504.689 | 810.462 | 0,44% | Saham |
| PRINCIPAL FINANCIAL GROUP INC | $19.966.658 | 789.196 | 0,43% | Saham |
| Bank of New York Mellon Corp | $19.243.919 | 760.629 | 0,41% | Saham |
| Allianz Asset Management GmbH | $19.157.034 | 757.195 | 0,41% | Saham |
| PANAGORA ASSET MANAGEMENT INC | $17.985.922 | 710.906 | 0,39% | Saham |
| Fisher Asset Management, LLC | $17.690.535 | 699.230 | 0,38% | Saham |
| FRED ALGER MANAGEMENT, LLC | $16.409.858 | 648.611 | 0,35% | Saham |
| RICE HALL JAMES & ASSOCIATES, LLC | $15.657.841 | 618.887 | 0,34% | Saham |
| AMERIPRISE FINANCIAL INC | $15.348.144 | 606.536 | 0,33% | Saham |
| MILLENNIUM MANAGEMENT LLC | $14.925.077 | 589.924 | 0,32% | Saham |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $14.771.456 | 583.852 | 0,32% | Saham |
| AQR CAPITAL MANAGEMENT LLC | $13.225.551 | 522.749 | 0,28% | Saham |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $12.903.000 | 510.000 | 0,28% | Saham |
| GLENMEDE TRUST CO NA | $12.360.212 | 488.546 | 0,27% | Saham |
| Hudson Bay Capital Management LP | $11.764.500 | 465.000 | 0,25% | Saham |
| UBS Group AG | $11.639.341 | 460.053 | 0,25% | Saham |
| JUPITER ASSET MANAGEMENT LTD | $11.599.190 | 458.466 | 0,25% | Saham |
Aktivis & pemilik 5%+ 6 saham
Investor yang mengajukan Jadwal 13D SEC — kepemilikan manfaat di atas 5% dengan niat untuk memengaruhi penerbit (kepemilikan aktivis, kampanye dewan, M&A). Setiap baris menunjukkan status terbaru yang diketahui dari posisi pengaju tersebut.
| Pengaju | Diajukan | Kepemilikan | Status | Tujuan | Pengajuan |
|---|---|---|---|---|---|
| Baker Bros. Advisors LP, Baker Bros. Advisors (GP) LLC, Julian C. Baker, Felix J. Baker, FBB3 LLC ×14 pengajuan | 26 Feb. 2026 | 25,40% | Amandemen | · | SEC |
| Baker Bros. Advisors, LLC, Felix J. Baker, Julian C. Baker ×4 pengajuan | 6 Juni 2013 | · | Pengajuan awal | · | SEC |
| Orang pelapor yang tidak diungkapkan, Orang pelapor yang tidak diungkapkan, Orang pelapor yang tidak diungkapkan | 2 Mei 2005 | · | Pengajuan awal | · | SEC |
| Orang pelapor yang tidak diungkapkan, Orang pelapor yang tidak diungkapkan, Orang pelapor yang tidak diungkapkan | 2 Mei 2005 | · | Pengajuan awal | · | SEC |
| Orang pelapor yang tidak diungkapkan, Orang pelapor yang tidak diungkapkan, Orang pelapor yang tidak diungkapkan | 2 Mei 2005 | · | Pengajuan awal | · | SEC |
| Oxford Bioscience Partners IV L.P., mRNA Fund II L.P., OBP Management IV L.P., Jeffrey T. Barnes, Mark P. Carthy, Jonathan J. Fleming, Michael E. Lytton, Alan G. Walton | 29 April 2005 | · | Pengajuan awal | Investasi pasif | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Orang dalam perusahaan 42 orang dalam · 24 pejabat · 21 direktur
| Orang Dalam | Peran | Aktivitas terakhir | Saham dimiliki | Beli 12m | Jual 12m | Bersih 12m |
|---|---|---|---|---|---|---|
| Adams Catherine Owen | Chief Executive Officer | 24 Maret 2026 M | 14.803 | 0 | 1 | $-249.932 |
| Stephen Davis | CEO | 19 Agu 2024 S | 186.555 | 0 | 0 | $0 |
| Uli Hacksell | CEO | 17 Feb. 2015 M | 115.549 | 0 | 0 | $0 |
| Mark C. Schneyer | EVP, CHIEF FINANCIAL OFFICER | 6 Agu 2026 M | 67.828 | 0 | 9 | $-1.126.027 |
| Elena Ridloff | EVP and CFO | 29 April 2021 M | 10.553 | 0 | 0 | $0 |
| Todd S. Young | EVP AND CFO | 15 Okt. 2018 A | · | 0 | 0 | $0 |
| Thomas H Aasen | EXEC VP, CFO AND CBO | 4 April 2014 M | 0 | 0 | 0 | $0 |
| Srdjan R. Stankovic | President | 21 Nov. 2022 M | 61.234 | 0 | 0 | $0 |
| Mark R Brann | President & CSO | 16 Juni 2006 S | 317.756 | 0 | 0 | $0 |
| Brendan Teehan | EVP, COO, HEAD OF COMMERCIAL | 17 Nov. 2024 M | 62.105 | 0 | 0 | $0 |
| Elizabeth H.Z. Thompson | EVP, Head of Research & Dev | 29 Juli 2026 M | 18.994 | 0 | 3 | $-506.411 |
| James Kihara | PRINCIPAL ACCOUNTING OFFICER | 26 Juni 2026 S | 13.088 | 0 | 8 | $-602.789 |
| Jennifer J Rhodes | EVP, CHIEF LEGAL OFFICER, SEC | 24 Maret 2026 M | 11.280 | 0 | 2 | $-245.022 |
| Thomas Garner | EVP, Chief Commercial Officer | 6 Maret 2026 A | · | 0 | 0 | $0 |
| Austin D. Kim | EVP,General Counsel, Secretary | 6 Jan. 2024 M | 46.901 | 0 | 0 | $0 |
| Douglas J Williamson | Executive VP, Research & Dev | 10 Feb. 2023 A | · | 0 | 0 | $0 |
| Michael J. Yang | EVP and CCO | 6 Jan. 2021 M | 8.059 | 0 | 0 | $0 |
| Eric Alejandro Miller | Controller & PAO | 15 Okt. 2019 M | 270 | 0 | 0 | $0 |
| Glenn Baity | EVP AND GC | 18 April 2018 A | 83.734 | 0 | 0 | $0 |
| Terrence O Moore | EVP, CHIEF COMMERCIAL OFFICER | 8 Maret 2017 A | 1.671 | 0 | 0 | $0 |
| Roger Mills | EVP, DEVELOPMENT AND CMO | 20 Maret 2015 A | 18.550 | 0 | 0 | $0 |
| Bo-Ragnar Tolf | VP/Mg. Dir. ACADIA Pharma AB | 8 Juli 2009 M | 20.000 | 0 | 0 | $0 |
| Brian Lundstrom | Sr. VP, Bus. Development | 7 Maret 2008 A | 0 | 0 | 0 | $0 |
| Robert E Davis | Exec. VP, Drug Discovery | 11 Maret 2005 A | · | 0 | 0 | $0 |
| Adora Ndu | Direktur | 29 Mei 2026 A | 32.908 | 0 | 0 | $0 |
| Elizabeth A. Garofalo | Direktur | 29 Mei 2026 A | 33.489 | 0 | 0 | $0 |
| Jonathan Poole | Direktur | 29 Mei 2026 A | 2.010 | 0 | 0 | $0 |
| James M Daly | Direktur | 29 Mei 2026 A | 12.148 | 0 | 1 | $-671.100 |
| Laura Brege | Direktur | 29 Mei 2026 A | 23.202 | 0 | 0 | $0 |
| Edmund Harrigan | Direktur | 29 Mei 2026 A | 43.148 | 0 | 0 | $0 |
| Daniel B Soland | Direktur | 29 Mei 2025 A | 44.041 | 0 | 0 | $0 |
| Mary Ann Gray | Direktur | 7 Juni 2016 M | 149.476 | 0 | 0 | $0 |
| Leslie L Iversen | Direktur | 18 April 2016 M | 36.127 | 0 | 0 | $0 |
| Lester J Ph D Kaplan | Direktur | 11 Agu 2015 M | 17.000 | 0 | 0 | $0 |
| William Mcdowall Wells | Direktur | 15 Juni 2015 A | 0 | 0 | 0 | $0 |
| Torsten Rasmussen | Direktur | 15 Juni 2015 A | 8.500 | 0 | 0 | $0 |
| Michael T Borer | Direktur | 15 Juni 2015 A | 0 | 0 | 0 | $0 |
| Gordon M Binder | Direktur | 12 Juni 2009 A | 14.364 | 0 | 0 | $0 |
| Alan G Walton | Direktur | 12 Juni 2009 A | 25.979 | 0 | 0 | $0 |
| Martien Van Osch | Direktur | 10 Juni 2005 A | 1.168.892 | 0 | 0 | $0 |
| GORDON CARL L | Direktur | 20 April 2005 A | 774.006 | 0 | 0 | $0 |
| John Joseph Kaiser | · | 20 Okt. 2008 A | · | 0 | 0 | $0 |
Orang dalam dari pengajuan SEC Form 3/4/5; bersih = hanya P/S pasar terbuka
Kepemilikan ETF Dimiliki oleh 59 ETF
Bobot mencerminkan kepemilikan ekuitas langsung (N-PORT) saja; dana berbasis leverage atau derivatif mungkin memiliki eksposur swap tambahan yang tidak ditampilkan.
| Dana | Bobot | Unit | Per tanggal | Sumber |
|---|---|---|---|---|
| IBRN · iShares Trust | 4,92% | 13.265 SH | 11 Sep. 2026 | Harian |
| PBE · Invesco Exchange-Traded Fund Trust | 1,84% | 383.853 SH | 2 Okt. 2026 | Harian |
| BBP · ETFis Series Trust I | 1,69% | 64.350 NS | 31 Juli 2026 | N-PORT |
| PSCH · Invesco Exchange-Traded Fund Trust … | 1,40% | 122.788 SH | 2 Okt. 2026 | Harian |
| RZG · Invesco Exchange-Traded Fund Trust | 0,96% | 57.480 SH | 2 Okt. 2026 | Harian |
| LABU · Direxion Shares ETF Trust | 0,71% | 134.777 NS | 31 Juli 2026 | N-PORT |
| ROSC · Lattice Strategies Trust | 0,62% | 14.725 NS | 31 Juli 2026 | N-PORT |
| VIOG · VANGUARD ADMIRAL FUNDS | 0,35% | 150.827 SH | 19 Agu 2026 | Harian |
| IBB · iShares Trust | 0,35% | 1.293.913 SH | 11 Sep. 2026 | Harian |
| IWO · iShares Trust | 0,24% | 1.215.092 SH | 11 Sep. 2026 | Harian |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,23% | 12.181 SH | 2 Okt. 2026 | Harian |
| PWS · Pacer Funds Trust | 0,20% | 1.841 NS | 31 Juli 2026 | N-PORT |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,19% | 137.860 SH | 19 Agu 2026 | Harian |
| BKSE · BNY Mellon ETF Trust | 0,19% | 6.256 NS | 31 Juli 2026 | N-PORT |
| VIOO · VANGUARD ADMIRAL FUNDS | 0,17% | 443.221 SH | 19 Agu 2026 | Harian |
| QVMS · Invesco Exchange-Traded Fund Trust … | 0,17% | 19.976 SH | 2 Okt. 2026 | Harian |
| FNY · First Trust Exchange-Traded AlphaDE… | 0,16% | 36.279 NS | 31 Juli 2026 | N-PORT |
| BBSC · J.P. Morgan Exchange-Traded Fund Tr… | 0,13% | 34.493 NS | 31 Juli 2026 | N-PORT |
| IWM · iShares Trust | 0,12% | 3.296.450 SH | 11 Sep. 2026 | Harian |
| ISCG · iShares Trust | 0,12% | 40.348 SH | 11 Sep. 2026 | Harian |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,10% | 137.841 SH | 2 Okt. 2026 | Harian |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,10% | 741.237 SH | 19 Agu 2026 | Harian |
| DFAS · Dimensional ETF Trust | 0,09% | 559.090 NS | 31 Juli 2026 | N-PORT |
| VBK · VANGUARD INDEX FUNDS | 0,09% | 1.699.377 SH | 19 Agu 2026 | Harian |
| FNX · First Trust Exchange-Traded AlphaDE… | 0,08% | 40.712 NS | 31 Juli 2026 | N-PORT |
| RWJ · Invesco Exchange-Traded Fund Trust … | 0,05% | 52.513 SH | 2 Okt. 2026 | Harian |
| FAD · First Trust Exchange-Traded AlphaDE… | 0,05% | 10.893 NS | 31 Juli 2026 | N-PORT |
| SMDX · Tidal Trust III | 0,05% | 2.295 NS | 31 Juli 2026 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 0,04% | 54.681 NS | 31 Juli 2026 | N-PORT |
| IEUS · iShares Trust | 0,04% | 7.263 SH | 11 Sep. 2026 | Harian |
| VXF · VANGUARD INDEX FUNDS | 0,04% | 1.457.036 SH | 19 Agu 2026 | Harian |
| VB · VANGUARD INDEX FUNDS | 0,04% | 2.944.095 SH | 19 Agu 2026 | Harian |
| VHT · VANGUARD WORLD FUND | 0,04% | 346.329 SH | 19 Agu 2026 | Harian |
| PDN · Invesco Exchange-Traded Fund Trust … | 0,04% | 13.154 SH | 2 Okt. 2026 | Harian |
| WSML · iShares Trust | 0,04% | 11.751 SH | 11 Sep. 2026 | Harian |
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0,03% | 4.009 SH | 2 Okt. 2026 | Harian |
| DXUV · Dimensional ETF Trust | 0,02% | 5.018 NS | 31 Juli 2026 | N-PORT |
| ISCF · iShares Trust | 0,02% | 13.099 SH | 11 Sep. 2026 | Harian |
| DFUV · Dimensional ETF Trust | 0,02% | 113.182 NS | 31 Juli 2026 | N-PORT |
| DFAC · Dimensional ETF Trust | 0,02% | 348.929 NS | 31 Juli 2026 | N-PORT |
| DFAT · Dimensional ETF Trust | 0,02% | 103.974 NS | 31 Juli 2026 | N-PORT |
| SCZ · iShares Trust | 0,02% | 238.968 SH | 9 Sep. 2026 | Harian |
| DCOR · Dimensional ETF Trust | 0,01% | 16.150 NS | 31 Juli 2026 | N-PORT |
| ESGV · VANGUARD WORLD FUND | 0,01% | 28.150 SH | 19 Agu 2026 | Harian |
| DFAU · Dimensional ETF Trust | 0,01% | 39.121 NS | 31 Juli 2026 | N-PORT |
| IWV · iShares Trust | 0,00% | 35.516 SH | 10 Sep. 2026 | Harian |
| ITOT · iShares Trust | 0,00% | 161.527 SH | 11 Sep. 2026 | Harian |
| DFUS · Dimensional ETF Trust | 0,00% | 35.634 NS | 31 Juli 2026 | N-PORT |
| IEFA · iShares Trust | 0,00% | 240.578 SH | 11 Sep. 2026 | Harian |
| TILT · FlexShares Trust | 0,00% | 632 NS | 31 Juli 2026 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 4.075.731 SH | 19 Agu 2026 | Harian |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0,00% | 100.076 SH | 19 Agu 2026 | Harian |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 10.781 SH | 19 Agu 2026 | Harian |
| IJR · iShares Trust | · | 7.728.763 SH | 10 Sep. 2026 | Harian |
| IJT · iShares Trust | · | 1.198.794 SH | 9 Sep. 2026 | Harian |
| XJR · iShares Trust | · | 17.544 SH | 31 Agu 2026 | Harian |
| ISCB · iShares Trust | · | 5.636 SH | 11 Sep. 2026 | Harian |
| SMLF · iShares Trust | · | 221.806 SH | 11 Sep. 2026 | Harian |
| SMMV · iShares Trust | · | 16.924 SH | 19 Agu 2026 | Harian |
ACAD Konsensus Analis Opini analis bullish dan bearish, target harga 12 bulan, potensi kenaikan
peringkat · 27 analis
BELI
Target median
$33.00
+65,4%
7 25,9%
Beli Kuat
14 51,9%
Beli
5 18,5%
Tahan
1 3,7%
Jual
0 0,0%
Jual Kuat
Target Harga 12 Bulan
19 analis · 2026-09-29Target rata-rata $32.16 +61,2%
Sekarang
Harga saat ini $19.95
Rendah$17.00
Rata-rata$32.16
Tinggi$49.00
Perbandingan rekan (sub-industri GICS) Metrik utama vs rekan sektor
Dasar FY, harga per penutupan akhir tahun fiskal terakhir setiap perusahaan.
| Ticker | Kapitalisasi Pasar | P/E | Pendapatan YoY | Margin Bersih | ROE | Margin Kotor |
|---|---|---|---|---|---|---|
| ACAD | $4.55B | 11.6 | 11.9% | 36.5% | 38.1% | · |
| IDYA | $3.04B | -27.0 | 3024.4% | -52.0% | -11.5% | · |
| VCYT | $3.34B | 51.3 | 16.0% | 12.8% | 5.2% | 70.1% |
| CELC | $4.81B | -26.3 | · | · | -244.3% | · |
| CDNA | $959M | -47.1 | 13.8% | -5.6% | -6.8% | · |
| DNLI | $2.58B | -5.6 | 204.7% | · | -50.2% | · |
| RCUS | $2.99B | -7.2 | -4.3% | -142.9% | -59.8% | · |
| ARQT | $3.58B | -223.4 | 91.3% | -4.3% | -9.8% | · |
| PGEN | $1.48B | -3.1 | 146.7% | -2588.2% | 3159.1% | · |
| PURR | $1.58B | 2.5 | · | 3229.8% | 24.8% | · |
| DYN | $3.23B | -5.6 | · | · | -57.8% | · |
Berita Terbaru Berita utama terbaru yang menyebutkan perusahaan ini
Sinyal Perdagangan Sinyal beli/jual terbaru dengan harga masuk dan rasio risiko/imbalan
BLUECHIP_DIP
Kedaluwarsa
risiko 1
imbalan 5,00
masuk
$21.20
R:R 5,00
BLUECHIP_DIP
Stop out
risiko 1
imbalan 4,79
masuk
$21.86
R:R 4,79
BLUECHIP_DIP
Stop out
risiko 1
imbalan 4,99
masuk
$22.45
R:R 4,99
Tidak ada sinyal terbuka saat ini — tidak ada kartu yang terisi, dan itu jujur.
Metrik Saya Daftar pantauan pribadi Anda — baris yang dipilih dari Fundamental Lengkap
Pilih metrik yang penting bagi Anda — klik + di sebelah baris mana pun di Fundamental Lengkap di atas.
Pilihan Anda disimpan dan mengikuti Anda di semua ticker.
Sumber: SEC 10-Q diajukan Agu 5, 2026